
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen is a promising clinical-stage biotechnology company that has developed a novel Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its strong pipeline of products, including PGN-EDO51 and PGN-EDODM1, along with a healthy cash position of $132M exiting the 1Q26 period, provide hope for further advancements in their cutting-edge technology. While there may be concerns around commercial execution, competition, and efficacy data, PepGen's recent completion of the 10mg/kg multi-dose cohort in the FREEDOM2 study and the promising data from its earlier 5mg/kg cohort show meaningful progress towards its goals. With this in mind, and considering possible funding needs, the company still remains attractive to investors.
Bears say
PepGen is facing several major challenges that may negatively impact the company's success, including uncertainty around the safety and efficacy of their lead product PGN-EDODM1, as observed in early clinical trials. Additionally, competition in the biotechnology space is increasing, which may impact the demand for PepGen's products in the future. As a result, the financial analyst maintains a negative outlook on PepGen's stock and has lowered their target price to $5 (from $9).
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares